HealthcareLarge capRs 95,440 crRs 122.9 cr traded a dayManufacturingHealthcarePharmaceuticals
Close on 10 September 2026
1,143.00
−0.17%
52-week range3% of the way up
1,135.601,375.70
Market cap
95,440 cr
P/E (TTM)
30.0×
industry 45×
EPS (TTM)
38.12
Revenue YoY
-5.5%
Q1 FY27
Profit YoY
-69.1%
Net margin
5.4%
-11.1pt vs a year ago
Growth trend
+6.0pt
vs last quarter’s YoY
1 month
-4.7%
Below 52w high
20.4%
RSI (14)
37
Daily swing
1.5%
average true range
Volume
1.4×
vs 20-day average
Traded
Rs 123 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Below the median
-8.8%
One-year return
Below the median
-12.2%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
-5.5%
Below the 52-week high
from the highest close of the year
-16.9%
1 week
−1.04%
1 month
−4.75%
3 months
−10.67%
6 months
−11.72%
1 year
−12.17%
The read
written from the numbers on this page
The evidence leans negative2 supporting, 7 against, 0 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.38 points over 20 sessions across 48,405 past signals
priced at 30× earnings against an industry median of 45× — 33% below its peers
Against
trading 9% below its 200-day average
at 3% of its 52-week range — nearly everyone who bought in the past year is underwater
down 12% over twelve months
revenue fell 6% year on year in the quarter ending 30 June 2026
net margin has narrowed from 15.1% to 5.4% across four quarters
futures show a short buildup — new sellers are committing capital
the future trades at a 0.58% discount to spot
Worth knowing
nothing the data supports either way
DRREDDY sits in Manufacturing, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 1,253, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working1
Rs 123 crore changes hands on a median day, so an ordinary order is not the reason it moves.
Rs 123 cr
Needs watching6
Net profit -69.1% year on year, Rs 1,410 cr to Rs 436 cr.
-69.1%Rs 1,410 crRs 436 cr
Dr Reddys Laboratories' profit growth was -69.1%, while revenue growth was -5.5%.
-69.1%-5.5%
Net margin fell from 16.4% to 5.4% this quarter versus last year.
16.4%5.4%
Trading 8.8% below its 200-day average.
-8.8%
Only 0.7% above its 52-week low.
+0.7%
A warning rule fires on it tonight: near a 52-week low.
Near a 52-week low
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 2 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
1 of 47 matched on 10 Sep
DRREDDY matches 1 of the 47 scans today, across 1 different kinds of evidence.
DRREDDY trades at 30× trailing earnings, above its median of 19× over this window — 60% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · M&A filings were typically +0.18pt vs the market over the next 5 sessions (n=1,722)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
net margin widened from 2.9% to 5.4%
Going against it
revenue fell 6% against the same quarter a year earlier
profit dropped 69% year on year
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
8,100
552
436
5.33
5.4%
Q4 FY26
31 Mar · consolidated
7,546
195
221
2.65
2.9%
Q3 FY26
31 Dec · consolidated
8,753
1,541
1,190
14.53
13.6%
Q2 FY26
30 Sep · consolidated
8,828
1,738
1,337
16.18
15.1%
Q1 FY26
30 Jun · consolidated
8,572
1,905
1,410
17.04
16.4%
Q4 FY25
31 Mar · consolidated
8,528
2,000
1,587
19.12
18.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-4.4%
Versus 200-day average-8.8%
Below 52-week high-16.9%
Above 52-week low+0.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)36.6
Higher closes in last 51 of 5
Six-month return−11.72%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)1.54%
Volume versus 20-day1.4x
Median daily turnoverRs 122.9 cr
Derivatives
near expiry 2026-09-29 · 2026-09-10
Short Buildup
Price down, open interest up. New sellers are committing capital. The most common state in a falling tape, and the one that unwinds hardest if it turns.
Futures basis versus spot-0.58%
Open interest change+2.5%
Put / call ratio0.57
Put wall (support)1,080
Call wall (resistance)1,200
Max pain1,160
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 68 classified companies
DRREDDY trades at 30.0× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 33%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.